Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ViiV’s Potential HIV Blockbuster Among Latest Drugs To Win EMA Nod

Executive Summary

A total of 13 new drugs have been recommended for pan-EU approval, while one has failed to meet the European Medicines Agency’s standards.

You may also be interested in...



GW Pharma's Cannabinoid Medicine Epidyolex Among CHMP Hopefuls

Seven new medicines, including GW Pharma's orphan cannabidiol product, Epidyolex, are due for an opinion from the European Medicines Agency this week on whether they should be recommended for pan-EU approval.

EU Ultomiris Approval Rounds Off A Good Week For Alexion’s Complement Franchise

A first EU approval for Ultomiris added to a label expansion for Soliris in the US made for a good seven days for Alexion’s C5 product portfolio.

ViiV's Dovato Could Challenge Status Quo In Naive EU HIV Patients

The approval of ViiV’s new once-daily, two-drug single-pill for HIV/AIDS could lead to a tough battle in Europe with established therapies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS125195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel